| 000 | 01724cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030455.0 | ||
| 008 | 110927s2011 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2011.Ba.P | ||
| 100 | 0 | _aBalqees Saeed Ahmed Mohamed Hazaa | |
| 245 | 1 | 2 |
_aA pharmaceutical study on some modified release solid dosage forms of certain statins / _cBalqees Saeed Ahmed Mohamed Hazaa ; Supervised Ahmed Abdelbary Abdelrahman , Howida Kamal Ibrahim |
| 246 | 1 | 5 | _aدراسة صيدلية على بعض الأشكال الصيدلية الصلبة محورة الإنطلاق لستاتينات معينة |
| 260 |
_aCairo : _bBalqees Saeed Ahmed Mohamed Hazaa , _c2011 |
||
| 300 |
_a188 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aSimvastatin is a potent inhibitor of 3- hydroxy - 3 - methy1 - glutary1 - coenzyme A ( HMG - CoA ) reductase and a cholesterol - lowering widely uaed to treat hypercholesterolemia . However, it gave poorly oral bioavailability ( < 5% ) due to its water - insolubility and extensive first pass metabolism by the CYP 450 isoform 3A4, and to a lesser degree, by CYP3A5, in the intestinal wall and liver | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aHypercholesterolemia | |
| 653 | 4 | _aOrodispersible | |
| 653 | 4 | _aSimvastain | |
| 700 | 0 |
_aAhmed Abdelbary Abdelrahman , _eSupervisor |
|
| 700 | 0 |
_aHowida Kamal Ibrahim , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c35435 _d35435 |
||